マーケットレポート詳細
ワクチンの世界市場：対象疾病別、タイプ別2026年予測
Vaccines Market by Technology (Recombinant, Toxoid, Conjugate, RNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Influenza, DTP, HPV, MMR, COVID-19), Route of Administration (IM, SC, Oral), End user (Pediatric, Adult) - Global Forecast to 2026
- 出版元：MarketsandMarkets
出版元について - 発行年：2022年1月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文293ページになります。
- 商品コード：MAM2838
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
COVID-19を含むワクチンの世界市場規模は2021年で1394億ドルと推計され、2026年には1492億ドルに増加する見込みです。一方で、COVID-19のワクチンを含まない場合の世界市場規模は2021年で414億ドル、2026年に672億ドルとなり、市場の平均年成長率は10.2%になると推測されます。
レポートはワクチンの世界市場について2026年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（技術別市場、タイプ別市場、等）を中心に構成されています。また競合状況、主要企業情報（17社）、COVID-19の影響、エコシステム分析などの分析も加味し、ワクチン市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆ワクチンの世界市場予測2019-2026年
・市場規模(US$)
◆技術別、市場-2026年
・結合型ワクチン
・組換えワクチン
・不活化ワクチン/サブユニットワクチン
・生ワクチン
・トキソイドワクチン
・ウイルスベクターワクチン
※(市場規模US$)
◆タイプ別、市場-2026年
・１価
・多価
※(市場規模US$)
◆対象疾病別、市場-2026年
・肺炎球菌感染症
・インフルエンザ
・混合ワクチン
・ヒトパピローマウイルス(HPV)
・髄膜炎菌性疾患
・帯状疱疹
・ロタウイルス
・MMR（麻疹/おたふくかぜ/風疹）
・水痘
・肝炎
・DPT(ジフテリア/百日咳/破傷風)
・ポリオ(急性灰白髄炎）
・COVID-19（新型コロナウィルス）
・その他疾病
※(市場規模US$)
◆投与経路別、市場-2026年
・筋肉内/皮下投与
・経口投与
・その他投与経路
※(市場規模US$)
◆エンドユーザー別、市場-2026年
・小児
・大人
※(市場規模US$)
◆主要国地域別市場-2026年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド、韓国
・その他アジア太平洋
中南米
・ブラジル
・その他中南米
中東アフリカ
※地域別、北米の国別に全セグメント別の細分化データ掲載、詳細は目次参照
※国別に技術別、タイプ別、投与経路別、エンドユーザー別の細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス(ドライバー、障壁、機会、課題)
・COVID-19の影響
・特許分析
・エコシステム分析
・ファイブフォース分析
・市場シェア分析
・競合状況
◆ワクチンの主要企業プロフィール動向
・GLAXOSMITHKLINE PLC
・MERCK & CO., INC.
・PFIZER, INC.
・SANOFI SA
・CSL LIMITED
・EMERGENT BIOSOLUTIONS, INC.
・JOHNSON & JOHNSON
・ASTRAZENECA PLC
・SERUM INSTITUTE OF INDIA PVT., LTD.
・BAVARIAN NORDIC A/S
・田辺三菱製薬株式会社
・第一三共株式会社
・PANACEA BIOTEC
・BIOLOGICAL E LIMITED
・BHARAT BIOTECH
・NOVAVAX, INC.
・FSUE NPO MICROGEN
（その他企業）
・SINOVAC BIOTECH LTD.
・INCEPTA VACCINE LTD.
・VALNEVA SE
・VBI VACCINES INC.
・PT BIO FARMA (PERSERO)
・INOVIO PHARMACEUTICALS, INC.
・CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
・INDIAN IMMUNOLOGICALS LIMITED
（全293頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1.... INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS.. 39
・ TABLE 1............... VACCINES MARKET: INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
・ FIGURE 1............................. VACCINES MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS.. 41
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2.... RESEARCH METHODOLOGY
2.1 RESEARCH DATA
・ FIGURE 2.................................................. RESEARCH DESIGN.. 44
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
・ FIGURE 3............ BREAKDOWN OF PRIMARIES: VACCINES MARKET
2.2 MARKET ESTIMATION METHODOLOGY
・ FIGURE 4........ MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
・ FIGURE 5........ MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
・ FIGURE 6... CAGR PROJECTIONS (SUPPLY-SIDE): VACCINES MARKET (EXCLUDING
COVID-19 VACCINES)
・ FIGURE 7 VACCINES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
2.4 DATA TRIANGULATION
・ FIGURE 8.......................... DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
3.... EXECUTIVE SUMMARY
・ FIGURE 9. VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
・ FIGURE 10............ COVID-19 VACCINES MARKET, BY TECHNOLOGY,
2021 VS. 2026 (USD MILLION)
・ FIGURE 11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2021 VS. 2026 (USD MILLION)
・ FIGURE 12... VACCINES MARKET, BY DISEASE INDICATION, 2021 VS. 2026 (USD MILLION)
・ FIGURE 13... VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD MILLION). 57
・ FIGURE 14......... VACCINES MARKET SHARE (EXCLUDING COVID-19 VACCINES), BY END USER, 2021 VS. 2026
・ FIGURE 15... GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET (EXCLUDING
COVID-19 VACCINES)
4.... PREMIUM INSIGHTS
4.1 VACCINES MARKET OVERVIEW (EXCLUDING COVID-19 VACCINES)
・ FIGURE 16............. GROWING PREVALENCE OF EMERGING AND RE-EMERGING INFECTIOUS DISEASES TO DRIVE MARKET GROWTH.. 60
4.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY AND COUNTRY (2020)
・ FIGURE 17.... CONJUGATE VACCINES ACCOUNTED FOR THE LARGEST SHARE OF
THE NORTH AMERICAN VACCINES MARKET IN 2020
4.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES
・ FIGURE 18.. ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE VACCINES MARKET FROM 2021 TO 2026
5.... MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 19................. VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 GROWING PREVALENCE OF EMERGING AND RE-EMERGING INFECTIOUS DISEASES
・ TABLE 2.................. GLOBAL INCIDENCE OF INFECTIOUS DISEASES
5.2.1.2 INCREASING FOCUS ON IMMUNIZATION PROGRAMS
5.2.1.3 GROWING GOVERNMENT SUPPORT FOR VACCINE DEVELOPMENT
・ TABLE 3.. NIH FUNDING FOR VACCINE RESEARCH, 2018–2022 (USD MILLION)
5.2.1.4 INCREASING INDUSTRY INITIATIVES TO ENHANCE VACCINE R&D
5.2.2 RESTRAINTS
5.2.2.1 HIGH COST OF VACCINE DEVELOPMENT
5.2.2.2 LOW PURCHASING POWER IN DEVELOPING COUNTRIES
5.2.3 OPPORTUNITIES
5.2.3.1 HIGH GROWTH PROSPECTS IN EMERGING MARKETS
5.2.3.2 FOCUS ON THERAPEUTIC VACCINES
5.2.3.3 USE OF ADJUVANTS IN VACCINES
5.2.4 CHALLENGES
5.2.4.1 INEQUI・ TABLE ACCESS TO VACCINES
・ TABLE 4.................. IMMUNIZATION COVERAGE, BY DISEASE, 2020
5.2.4.2 VACCINE MISINFORMATION
5.3 IMPACT OF COVID-19 ON THE VACCINES MARKET
・ TABLE 5.......... APPROVED COVID-19 VACCINES (NOVEMBER 2021)
・ TABLE 6....................................... COVID-19 VACCINES PIPELINE
・ FIGURE 20 VACCINES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019–2021 (USD BILLION)
5.4 RANGES/SCENARIO
・ FIGURE 21.... SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE VACCINES MARKET
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
・ FIGURE 22 REVENUE SHIFT & NEW REVENUE POCKETS FOR VACCINE PROVIDERS
5.6 PATENT ANALYSIS
・ FIGURE 23 PATENTS GRANTED FOR VACCINES IN THE LAST 10 YEARS
・ TABLE 7...... INDICATIVE LIST OF PATENTS IN THE VACCINES MARKET
5.7 PRICING ANALYSIS
・ TABLE 8 MEDIAN PRICE PER DOSE OF SOME VACCINES (2020) (USD)
5.8 VALUE CHAIN ANALYSIS
・ FIGURE 24. VALUE CHAIN ANALYSIS OF THE VACCINES MARKET: R&D AND CLINICAL TRIAL PHASE CONTRIBUTES MAXIMUM VALUE
5.9 ECOSYSTEM ANALYSIS
・ FIGURE 25.................. ECOSYSTEM ANALYSIS: VACCINES MARKET
5.10 REGULATORY LANDSCAPE
・ FIGURE 26......... REGULATORY APPROVAL PROCESS FOR VACCINES
5.10.1 NORTH AMERICA
5.10.2 EUROPE
・ TABLE 9............................ REGULATORY AUTHORITIES IN EUROPE
5.10.3 ASIA PACIFIC
・ TABLE 10.................... REGULATORY AUTHORITIES IN ASIA PACIFIC
5.10.4 REST OF THE WORLD
5.11 PORTER’S FIVE FORCES ANALYSIS
・ TABLE 11...... VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF BUYERS.. 83
5.11.4 BARGAINING POWER OF SUPPLIERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY PIPELINE PRODUCTS
・ TABLE 12...... KEY PIPELINE VACCINES: GLAXOSMITHKLINE PLC (UK)
・ TABLE 13..................... KEY PIPELINE VACCINES: PFIZER, INC. (US)
・ TABLE 14............ KEY PIPELINE VACCINES: MERCK & CO., INC. (US)
・ TABLE 15.............. KEY PIPELINE VACCINES: SANOFI S.A. (FRANCE)
5.13 NEW VACCINE OPPORTUNITIES
5.13.1 HIV
5.13.1.1 HIV VACCINES PIPELINE
5.13.1.2 HIV VACCINES: PUBLIC-PRIVATE INITIATIVES AND FUNDING
5.13.2 MALARIA
5.13.2.1 MALARIA VACCINES PIPELINE
5.13.2.2 MALARIA VACCINES: PUBLIC-PRIVATE INITIATIVES AND FUNDING
5.13.3 ZIKA
5.13.3.1 ZIKA VACCINES PIPELINE
5.13.3.2 ZIKA VACCINES: PUBLIC-PRIVATE INITIATIVES AND FUNDING
5.13.4 EBOLA
5.13.4.1 EBOLA VACCINES PIPELINE
5.13.4.2 EBOLA VACCINES: PUBLIC-PRIVATE INITIATIVES AND FUNDING
5.13.4.3 EBOLA PROJECTS FUNDED BY EC (2014–2020)
6.... VACCINES MARKET, BY TECHNOLOGY
6.1 INTRODUCTION
・ TABLE 16. VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 17.... COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
6.2 CONJUGATE VACCINES
6.2.1 CONJUGATE VACCINES HOLD THE LARGEST SHARE OF THE MARKET
・ TABLE 18.......... COST OF PEDIATRIC MENINGOCOCCAL CONJUGATE VACCINES AVAILABLE IN THE US
・ TABLE 19. COST OF ADULT MENINGOCOCCAL CONJUGATE VACCINES AVAILABLE IN
THE US
・ TABLE 20..... CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)
・ TABLE 21........... NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 22...... EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 98
・ TABLE 23 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 98
・ TABLE 24............. LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
6.3 RECOMBINANT VACCINES
6.3.1 LACK OF POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES ARE DRIVING R&D ON RECOMBINANT VACCINES
・ TABLE 25....................... EXAMPLES OF RECOMBINANT VACCINES
・ TABLE 26 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)
・ TABLE 27....... NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 28.. EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 100
・ TABLE 29............ ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 30......... LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
6.4 INACTIVATED & SUBUNIT VACCINES
6.4.1 EASE OF STORAGE AND TRANSPORTATION HAVE MADE INACTIVATED & SUBUNIT VACCINES POPULAR
・ TABLE 31........... EXAMPLES OF INACTIVATED & SUBUNIT VACCINES
・ TABLE 32.. INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
・ TABLE 33...... NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 34...... EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 103
・ TABLE 35 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 36........ LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
6.5 LIVE ATTENUATED VACCINES
6.5.1 ISSUES IN PRESERVING AND MAINTAINING LIVE ATTENUATED VACCINES HAVE SLOWED MARKET GROWTH
・ TABLE 37.................... EXAMPLES OF LIVE ATTENUATED VACCINES
・ TABLE 38. LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)
・ TABLE 39.... NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 106
・ TABLE 40............... EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 41......... ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 42...... LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING
COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 107
6.6 TOXOID VACCINES
6.6.1 COMPANY INITIATIVES AND THE INTRODUCTION OF NEW VACCINES WILL SUPPORT MARKET GROWTH
・ TABLE 43................................. EXAMPLES OF TOXOID VACCINES
・ TABLE 44.......... TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION). 108
・ TABLE 45. NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 109
・ TABLE 46.. EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 47..... ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 109
・ TABLE 48.. LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 110
6.7 VIRAL VECTOR VACCINES
6.7.1 VIRAL VECTOR VACCINES USE THE BODY’S OWN CELLS TO PRODUCE ANTIGENS
・ TABLE 49.......... EXAMPLES OF RECENTLY LAUNCHED VIRAL VECTOR VACCINES
・ TABLE 50.. VIRAL VECTOR VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)
7.... VACCINES MARKET, BY TYPE
7.1 INTRODUCTION
・ TABLE 51.. VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION)
・ TABLE 52. VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION)
7.2 MONOVALENT VACCINES
7.2.1 MONOVALENT VACCINES DOMINATE THE VACCINES MARKET
・ TABLE 53......................... EXAMPLES OF MONOVALENT VACCINES
・ TABLE 54.. MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)
・ TABLE 55... NORTH AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 56 EUROPE: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 57....... ASIA PACIFIC: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 58.... LATIN AMERICA: VACCINES MARKET FOR MONOVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)
7.3 MULTIVALENT VACCINES
7.3.1 INCREASING INITIATIVES BY COMPANIES TO DEVELOP NEW MULTIVALENT VACCINES TO DRIVE MARKET GROWTH
・ TABLE 59......................... EXAMPLES OF MULTIVALENT VACCINES
・ TABLE 60.. MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)
・ TABLE 61... NORTH AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 62 EUROPE: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 63........ ASIA PACIFIC: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 64..... LATIN AMERICA: VACCINES MARKET FOR MULTIVALENT VACCINES (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)
8.... VACCINES MARKET, BY DISEASE INDICATION
8.1 INTRODUCTION
・ TABLE 65. VACCINES MARKET, BY DISEASE INDICATION, 2019–2026 (USD MILLION)
8.2 PNEUMOCOCCAL DISEASE
8.2.1 PNEUMOCOCCAL DISEASE IS THE LARGEST DISEASE INDICATION SEGMENT OF THE MARKET
・ TABLE 66....... LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN
THE MARKET
・ TABLE 67 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2019–2026 (USD MILLION)
・ TABLE 68.... NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 69. PNEUMOCOCCAL DISEASE VACCINES MARKET, BY BUYER,
2019–2026 (MILLION DOSES)
8.3 INFLUENZA.. 124
8.3.1 RISING DEMAND FOR INFLUENZA VACCINES FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET GROWTH
・ TABLE 70. LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET
・ TABLE 71... INFLUENZA VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 72........ NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.4 COMBINATION VACCINES
8.4.1 INCREASING DEMAND FOR ALL-IN-ONE VACCINES IS DRIVING THE GROWTH OF THIS SEGMENT
・ TABLE 73.......... LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES IN
THE MARKET
・ TABLE 74...... COMBINATION VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 75... NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.5 HPV
8.5.1 HPV VACCINES MARKET TO GROW AT THE HIGHEST RATE DURING
THE FORECAST PERIOD
・ TABLE 76. LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
・ TABLE 77..... HPV VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 78... NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 79. HPV VACCINES MARKET, BY BUYER, 2019–2026 (MILLION DOSES)
8.6 MENINGOCOCCAL DISEASE
8.6.1 RISING INCIDENCE OF MENINGOCOCCAL DISEASE TO SUPPORT
THE GROWTH OF THIS SEGMENT
・ TABLE 80..... LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES IN THE MARKET
・ TABLE 81.......... MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION,
2019–2026 (USD MILLION)
・ TABLE 82... NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)
8.7 HERPES ZOSTER
8.7.1 HERPES ZOSTER VACCINES TO WITNESS S・ TABLE DEMAND DURING
THE FORECAST PERIOD
・ TABLE 83............. HERPES ZOSTER VACCINES MARKET, BY REGION,
2019–2026 (USD MILLION)
・ TABLE 84. NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.8 ROTAVIRUS.. 133
8.8.1 RISING INCIDENCE OF ROTAVIRUS INFECTIONS TO DRIVE MARKET GROWTH
・ TABLE 85 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET
・ TABLE 86.. ROTAVIRUS VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 87....... NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 88.... ROTAVIRUS VACCINES MARKET, BY BUYER, 2019–2026 (MILLION DOSES)
8.9 MMR
8.9.1 RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA IS SUPPORTING THE GROWTH OF THIS SEGMENT
・ TABLE 89 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET
・ TABLE 90... MMR VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 91. NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.10 VARICELLA.. 136
8.10.1 PROMOTION OF IMMUNIZATION PROGRAMS TO DRIVE THE DEMAND FOR VARICELLA VACCINES
・ TABLE 92. LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET
・ TABLE 93... VARICELLA VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 94........ NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.11 HEPATITIS.. 138
8.11.1 HIGH PREVALENCE OF HEPATITIS INFECTIONS TO DRIVE THE DEMAND FOR IMMUNIZATION
・ TABLE 95.. LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET
・ TABLE 96.... HEPATITIS VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 97......... NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.12 DTP
8.12.1 INCREASING ACCESSIBILITY OF DTP VACCINES IN DEVELOPING COUNTRIES TO DRIVE MARKET GROWTH
・ TABLE 98.. LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET
・ TABLE 99..... DTP VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 100. NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.13 POLIO
8.13.1 GOVERNMENT INITIATIVES TO SUPPORT THE GROWTH OF THIS SEGMENT
・ TABLE 101 POLIO VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 102............ NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.14 COVID-19
8.14.1 EMERGENCE OF SARS-COV-2 VARIANTS COULD MAKE BOOSTER DOSES NECESSARY
・ TABLE 103.......... LIST OF WHO PREQUALIFIED COVID-19 VACCINES
・ TABLE 104... COVID-19 VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 105........ NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 106... COVID-19 VACCINE DELIVERIES, BY COUNTRY (MILLION DOSES)
8.15 OTHER DISEASE INDICATIONS
・ TABLE 107 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS
・ TABLE 108 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,
2019–2026 (USD MILLION)
・ TABLE 109.......... NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS,
BY COUNTRY, 2019–2026 (USD MILLION)
9.... VACCINES MARKET, BY ROUTE OF ADMINISTRATION
9.1 INTRODUCTION
・ TABLE 110... VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 111.... VACCINES MARKET (INCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
9.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
9.2.1 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION ACCOUNTED FOR THE LARGEST MARKET SHARE
・ TABLE 112 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
・ TABLE 113............. VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION,
2019–2026 (USD MILLION)
・ TABLE 114.................... NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 115. EUROPE: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 116. ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 117..................... LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)
9.3 ORAL ADMINISTRATION
9.3.1 POSSIBILITY OF IRRITATION OF THE GASTRIC MUCOSA IS LIMITING
THE GROWTH OF THIS SEGMENT
・ TABLE 118............ VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
・ TABLE 119............ NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 120 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 121................. ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 122.............. LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)
9.4 OTHER ROUTES OF ADMINISTRATION
・ TABLE 123................... VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION)
・ TABLE 124 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 125...... EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 126 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 127. LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY,
2019–2026 (USD MILLION)
10.. VACCINES MARKET, BY END USER
10.1 INTRODUCTION
・ TABLE 128 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER,
2019–2026 (USD MILLION)
10.2 PEDIATRIC VACCINES
10.2.1 PEDIATRIC VACCINES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET
・ TABLE 129.... PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY REGION, 2019–2026 (USD MILLION)
・ TABLE 130........... NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 131...... EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 160
・ TABLE 132 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 160
・ TABLE 133............. LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION)
10.3 ADULT VACCINES
10.3.1 ADULT VACCINES SEGMENT TO GROW AT THE HIGHEST CAGR DURING
THE FORECAST PERIOD
・ TABLE 134.......... ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2019–2026 (USD MILLION). 162
・ TABLE 135 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 162
・ TABLE 136. EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 137..... ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 163
・ TABLE 138.. LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2019–2026 (USD MILLION). 163
11.. VACCINES MARKET, BY REGION
11.1 INTRODUCTION
・ FIGURE 27.................. VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES (EXCLUDING COVID-19 VACCINES)
・ TABLE 139......... VACCINES MARKET, BY REGION, 2019–2026 (USD MILLION)
・ TABLE 140 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION,
2019–2026 (USD MILLION)
11.2 NORTH AMERICA
・ FIGURE 28........... NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
・ TABLE 141 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 142 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)
・ TABLE 143 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 144 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 145 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 146 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.2.1 US
11.2.1.1 THE US IS THE LARGEST MARKET FOR VACCINES GLOBALLY
・ TABLE 147.............. US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)
・ TABLE 148.............. US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 149.............. US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION)
・ TABLE 150.............. US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 151.............. US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
11.2.2 CANADA
11.2.2.1 HIGH INCIDENCE OF INFECTIOUS DISEASES IS DRIVING THE DEMAND FOR VACCINES IN THE COUNTRY
・ TABLE 152...... CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)
・ TABLE 153...... CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 154...... CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 155...... CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 156...... CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.3 EUROPE
・ TABLE 157....... EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 158....... EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)
・ TABLE 159....... EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 160....... EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 161....... EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 162....... EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 SIGNIFICANT INVESTMENTS IN R&D TO SUPPORT MARKET GROWTH
・ TABLE 163.... GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 164.... GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 165.... GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 166.... GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.3.2 UK
11.3.2.1 LAUNCH OF NEW PRODUCTS AND COLLABORATIONS TO SUPPORT MARKET GROWTH IN THE UK IN THE COMING YEARS
・ TABLE 167.............. UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 168.............. UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION)
・ TABLE 169.............. UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 170.............. UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 FAVORABLE GOVERNMENT INITIATIVES FOR IMMUNIZATION TO SUPPORT MARKET GROWTH IN FRANCE
・ TABLE 171....... FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 172....... FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 173....... FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 174....... FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.3.4 ITALY
11.3.4.1 ITALY IS THE THIRD-LARGEST DONOR FOR THE INTERNATIONAL FINANCE FACILITY FOR IMMUNIZATION
・ TABLE 175........... ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 176........... ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 177........... ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 178........... ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION). 186
11.3.5 SPAIN
11.3.5.1 INCREASING INVESTMENTS IN VACCINE DEVELOPMENT BY PRIVATE ORGANIZATIONS TO SUPPORT MARKET GROWTH IN SPAIN
・ TABLE 179......... SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 180......... SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 181......... SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 182......... SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION). 188
11.3.6 REST OF EUROPE
・ TABLE 183............ ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 184............ ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE,
2019–2026 (USD MILLION)
・ TABLE 185............ ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 186............ ROE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
11.4 ASIA PACIFIC
・ TABLE 187 ASIA PACIFIC: HEALTHCARE EXPENDITURE PER CAPITA, BY COUNTRY,
2017 VS. 2018 VS. 2019 (USD)
・ FIGURE 29 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES)
・ TABLE 188 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 189 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)
・ TABLE 190 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 191 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 192 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 193 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.4.1 CHINA
11.4.1.1 GROWING INVESTMENTS IN THE BIOTECHNOLOGY SECTOR TO DRIVE MARKET GROWTH IN CHINA
・ TABLE 194......... CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 195......... CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 196......... CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 197......... CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 GOVERNMENT INITIATIVES FOR INCREASING THE ACCESSIBILITY OF VACCINES TO DRIVE MARKET GROWTH IN JAPAN
・ TABLE 198......... JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 199......... JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 200......... JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 201......... JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.4.3 INDIA
11.4.3.1 GROWTH OF THE BIOTECHNOLOGY SECTOR AND DEVELOPMENT OF NEW VACCINES TO SUPPORT MARKET GROWTH IN INDIA
・ TABLE 202.......... INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 203.......... INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 204.......... INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 205.......... INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION). 200
11.4.4 SOUTH KOREA
11.4.4.1 STRONG GOVERNMENT BOOST TO DEVELOP VACCINE HUBS IN THE COUNTRY IS EXPECTED TO DRIVE MARKET GROWTH
・ TABLE 206 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 207 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 208 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 209 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.4.5 REST OF ASIA PACIFIC
・ TABLE 210...... ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 211...... ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 212...... ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 213...... ROAPAC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.5 LATIN AMERICA
・ TABLE 214. LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 215. LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY DISEASE INDICATION, 2019–2026 (USD MILLION)
・ TABLE 216. LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 217. LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 218. LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 219. LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 RISING FOCUS ON VACCINATION FROM GOVERNMENTAL AND NON-GOVERNMENTAL ORGANIZATIONS TO DRIVE MARKET GROWTH
・ TABLE 220........ BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 221........ BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 222........ BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 223........ BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY END USER, 2019–2026 (USD MILLION)
11.5.2 REST OF LATIN AMERICA
・ TABLE 224.......... ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 225.......... ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 226.......... ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES),
BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 227.......... ROLA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION). 210
11.6 MIDDLE EAST AND AFRICA
11.6.1 HIGH DEMAND FOR VACCINES DUE TO THE PREVALENCE OF INFECTIOUS DISEASES WILL DRIVE MARKET GROWTH
・ TABLE 228 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2019–2026 (USD MILLION)
・ TABLE 229 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2019–2026 (USD MILLION)
・ TABLE 230 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 231 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2019–2026 (USD MILLION)
・ TABLE 232 MIDDLE EAST & AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2019–2026 (USD MILLION)
12.. COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
・ FIGURE 30....... KEY PLAYER STRATEGIES IN THE VACCINES MARKET, 2018-2021
12.3 MARKET SHARE ANALYSIS
・ FIGURE 31..... VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
・ FIGURE 32.. REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE VACCINES MARKET, 2016–2020
12.5 COMPANY EVALUATION QUADRANT
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
・ FIGURE 33. VACCINES MARKET: COMPANY EVALUATION QUADRANT, 2020
12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
・ FIGURE 34.. VACCINES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
12.7 DISEASE INDICATION FOOTPRINT OF COMPANIES
・ TABLE 233... DISEASE INDICATION PORTFOLIO ANALYSIS: VACCINES MARKET (2020)
12.8 REGIONAL FOOTPRINT OF COMPANIES
・ TABLE 234...... REGIONAL FOOTPRINT ANALYSIS: VACCINES MARKET (2020)
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHERS & APPROVALS
・ TABLE 235 VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2018–NOVEMBER 2021
12.9.2 DEALS
・ TABLE 236. VACCINES MARKET: DEALS, JANUARY 2018–NOVEMBER 2021
12.9.3 OTHER DEVELOPMENTS
・ TABLE 237................ VACCINES MARKET: OTHER DEVELOPMENTS,
JANUARY 2018–NOVEMBER 2021
13.. COMPANY PROFILES
(BUSINESS OVERVIEW, PRODUCTS/SERVICES/SOLUTIONS OFFERED, MNM VIEW, KEY STRENGTHS AND RIGHT TO WIN, STRATEGIC CHOICES MADE, WEAKNESSES AND COMPETITIVE THREATS, RECENT DEVELOPMENTS)*
13.1 KEY COMPANIES
13.1.1 GLAXOSMITHKLINE PLC
・ TABLE 238.............. GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW
・ FIGURE 35.... GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2020)
13.1.2 MERCK & CO., INC.
・ TABLE 239.................... MERCK & CO., INC.: BUSINESS OVERVIEW
・ FIGURE 36.......... MERCK & CO., INC.: COMPANY SNAPSHOT (2020)
13.1.3 PFIZER, INC.
・ TABLE 240............................. PFIZER, INC.: BUSINESS OVERVIEW
・ FIGURE 37.................. PFIZER, INC.: COMPANY SNAPSHOT (2020)
13.1.4 SANOFI SA
・ TABLE 241............................... SANOFI SA: BUSINESS OVERVIEW
・ FIGURE 38.................... SANOFI SA: COMPANY SNAPSHOT (2020)
13.1.5 CSL LIMITED
・ TABLE 242............................ CSL LIMITED: BUSINESS OVERVIEW
・ FIGURE 39.................. CSL LIMITED: COMPANY SNAPSHOT (2020)
13.1.6 EMERGENT BIOSOLUTIONS, INC. 258
・ TABLE 243... EMERGENT BIOSOLUTIONS, INC.: BUSINESS OVERVIEW
・ FIGURE 40.... MERGENT BIOSOLUTIONS, INC.: COMPANY SNAPSHOT (2020)
13.1.7 JOHNSON & JOHNSON
・ TABLE 244................ JOHNSON & JOHNSON: BUSINESS OVERVIEW
・ FIGURE 41...... JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020)
13.1.8 ASTRAZENECA PLC
・ TABLE 245.................... ASTRAZENECA PLC: BUSINESS OVERVIEW
・ FIGURE 42.......... ASTRAZENECA PLC: COMPANY SNAPSHOT (2020)
13.1.9 SERUM INSTITUTE OF INDIA PVT., LTD.
・ TABLE 246........... SERUM INSTITUTE OF INDIA PVT. LTD.: BUSINESS OVERVIEW
13.1.10 BAVARIAN NORDIC A/S
・ TABLE 247.............. BAVARIAN NORDIC A/S: BUSINESS OVERVIEW
・ FIGURE 43.... BAVARIAN NORDIC A/S: COMPANY SNAPSHOT (2020)
13.1.11 MITSUBISHI TANABE PHARMA CORPORATION
・ TABLE 248 MITSUBISHI TANABE PHARMA CORPORATION: BUSINESS OVERVIEW
13.1.12 DAIICHI SANKYO COMPANY, LIMITED
・ TABLE 249............ DAIICHI SANKYO COMPANY, LIMITED: BUSINESS OVERVIEW
・ FIGURE 44............ DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2020)
13.1.13 PANACEA BIOTEC
・ TABLE 250...................... PANACEA BIOTEC: BUSINESS OVERVIEW
・ FIGURE 45............ PANACEA BIOTEC: COMPANY SNAPSHOT (2020)
13.1.14 BIOLOGICAL E LIMITED
・ TABLE 251............... BIOLOGICAL E LIMITED: BUSINESS OVERVIEW
13.1.15 BHARAT BIOTECH
・ TABLE 252...................... BHARAT BIOTECH: BUSINESS OVERVIEW
13.1.16 NOVAVAX, INC.
・ TABLE 253.......................... NOVAVAX, INC.: BUSINESS OVERVIEW
・ FIGURE 46............... NOVAVAX, INC.: COMPANY SNAPSHOT (2020)
13.1.17 FSUE NPO MICROGEN
・ TABLE 254... FSUE NPO MICROGEN: BUSINESS OVERVIEW
*BUSINESS OVERVIEW, PRODUCTS/SERVICES/SOLUTIONS OFFERED, MNM VIEW, KEY STRENGTHS AND RIGHT TO WIN, STRATEGIC CHOICES MADE, WEAKNESSES AND COMPETITIVE THREATS, RECENT DEVELOPMENTS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
13.2 OTHER COMPANIES
13.2.1 SINOVAC BIOTECH LTD.
13.2.2 INCEPTA VACCINE LTD.
13.2.3 VALNEVA SE
13.2.4 VBI VACCINES INC.
13.2.5 PT BIO FARMA (PERSERO)
13.2.6 INOVIO PHARMACEUTICALS, INC. 292
13.2.7 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.
13.2.8 INDIAN IMMUNOLOGICALS LIMITED
14.. APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS